AANA Journal course. Update for nurse anesthetists - Cyclodextrin introduction to anesthesia practice: Form, function, and application

AANA Journal

Volumn 75, Issue 4, 2007, Pages 289-296

  Welliver, Mark ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF NORTH FLORIDA   (United States)

Author keywords

Anesthesia; Cyclodextrins; Encapsulation; Host guest assembly inclusion complex; Modified cyclodextrins derivatives

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALFENTANIL; BENZODIAZEPINE DERIVATIVE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CARBOXYL THIOETHER GAMMA CYCLODEXTRIN; CYCLODEXTRIN; ETOMIDATE; ITRACONAZOLE; LOCAL ANESTHETIC AGENT; LOFENTANIL; MIDAZOLAM; MORPHINE; NUTRACEUTICAL; OLIGOSACCHARIDE; OPIATE; PROPOFOL; PROPYLENE GLYCOL; PROSTAGLANDIN E1; SUFENTANIL; SUGAMMADEX; UNCLASSIFIED DRUG; VORICONAZOLE; ZIPRASIDONE; DRUG CARRIER; EXCIPIENT;

ANALYTIC METHOD; ANESTHESIA; AQUEOUS SOLUTION; ARTICLE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG SAFETY; DRUG STABILITY; FOOD INDUSTRY; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MEDICAL PRACTICE; NONHUMAN; RESPIRATION DEPRESSION; ANESTHESIOLOGY; CHEMISTRY; DRUG INTERACTION; EDUCATION; METHODOLOGY; NURSE ANESTHETIST; NURSING; REVIEW; SOLUBILITY;

ANESTHESIA; ANESTHESIOLOGY; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DRUG CARRIERS; DRUG INTERACTIONS; DRUG STABILITY; EXCIPIENTS; HUMANS; NURSE ANESTHETISTS; SOLUBILITY;

EID: 34547868548     PISSN: 00946354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Szejtli J. Past, present and future of cyclodextrin research. Pure Appl Chem. 2004;76:1825-1845.
2. Kamada M, Hirayama F, Udo K, Yano H, Arima H, Uekama K. Cyclodextrin conjugate-based controlled release system: repeated-and prolonged-releases of ketoprofen after oral administration in rats. J Control Release. 2002;82:407-416.
3. Tarantino LM. Agency response letter GRAS Notice No. GRN 000155. Dec. 22, 2004. Available at: http://www.cfsan.fda.gov/~rdb/opa-g155.html. Accessed May 22, 2006.
4. Rulis AM. Agency response letter GRAS Notice GRN 000074. October 25, 2001. Available at: http://www.cfsan.fda.gov/~rdb/opa-g074.html. Accessed May 22, 2006.
5. Rulis AM. Agency response letter GRAS Notice GRN 000046. September 22, 2000. Available at: http://www.cfsan.fda.gov/~rdb/opa-g046.html. Accessed May 22, 2006.
6. Stella VJ, Rao VM, Zannou EA, Zia VV. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev. 1999;36:3-16.
7. Thompson D, Chaubal MV. Cyclodextrins (CDS): excipients by definition, drug delivery system by function, part I: injectable applications. Drug Delivery Technol. 2002;2:34-38.
8. McIntosh MP, Schwarting N, Rajewski RA. In vitro and in vivo evaluation of a sulfobutyl ether β-cyclodextrin enabled etomidate formulation. J Pharm Sci. 2004;93:2582-2594.
9. Doenicke A, Roizen MF, Nebauer AE, Kugler A, Hoernecke R, Beger-Hintzen H. A comparison of two formulations for etomidate, 2-hydroxypropyl-beta- cyclodextrin (HPCD) and propylene glycol. Anesth Analg. 1994;9:933-939.
10. Marttin E, Verhoef JC, Merkus FW. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J Drug Target. 1998;6:17-36.
11. Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci. 2004;26:137-142.
12. Loftsson T, Gudmundsdottir H, Sigurjonsdottir JE, et al. Cyclodextrin solubilization of benzodiazepines: formation of midazolam nasal spray. Int J Pharm. 2001;212:29-40.
13. Gudmundsdottir H, Sigurjonsdottir JF, Masson M, Fjalldal O, Stefansson E, Loftsson T. Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. Pharmazie. 2001;56:963-966.
14. Jang J, Yaksh TL, Hill HF. Use of 2-hydroxypropyl-beta-cyclodextrin as an intrathecal drug vehicle with opioids. Pharmacology. 1992;261:592-600.
15. Bernards CM. Effect of (hydroxypropyl)-beta-cyclodextrin on flux of morphine, fentanyl, sufentanil and alfentanil through the spinal meninges of monkey. J Pharm Sci. 1994;83:620-622.
16. Dollo G, Le Corre P, Chevanne F, Le Verge R. Inclusion complexation of amide-type local anesthetics with beta-cyclodextrin and its derivatives, II: evaluation of affinity constants and in vitro transfer rate constants. Int J Pharm. 1996;136:165-174.
17. Dollo G, Thompson DO, Le Corre P, Chevanne F, Le Verge R. Inclusion complexation of amide-typed local anesthetics with β-cyclodextrin and its derivatives, III: biopharmaceutics of bupivacaine-SBE7-pCD complex following percutaneous sciatic nerve administration in rabbits. Int J Pharm. 1998;164:11-19.
18. Li N, Duan J, Chen H, Chen G. Determination of the binding constant for the inclusion complex between procaine hydrochloride and γ-cyclodextrin by capillary electrophoresis. Talanta. 2003;59:493-499.
19. Pinto LMA, Franceto LF, Santana MHA, Pertinhez TA, Junior SO, de Paula E. Physio-chemical characterization of benzocaine-β-cyclodextrin inclusion complexes. J Pharm Biomed Anal. 2005;39:956-963.
20. Egan TD, Kern SE, Johnson KB, Pace NL. The pharmacokinetics of propofol in a modified cyclodextrin formation (Captisol®) versus propofol in a lipid formulation (Diprivan®): an electroencephalographic and hemodynamic study in a porcine model. Anesth Analg. 2003;97:72-79.
21. Vierstein H, Stumpf C, Spiegel P, Reiter S. Preparation and central action of propofol/hydroxypropyl-beta-cyclodextrin complexes in rabbits. Arzneim-Forsch/Drug Res. 1993;43:818-821.
22. Bielen SJ, Lysko GS, Gough WB. The effect of a cyclodextrin vehicle on the cardiovascular profile of propofol in rats. Anesth Analg. 1996;82:920-924.
23. Thompson D, Mosher GL, inventors; CyDex, Inc, assignee. Formulations containing propofol and a sulfoalkyl cyclodextrin. US patent 7,034,013. April 25, 2006. Available at: http://patft.uspto.gov/netacgi/nph-Parser?Sect1= PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r= 1&f=G&1=50&col=AND&d=PTXT&s1=propofol&s2= sulfoalkyl&OS=propofol+AND+sulfoalkyl&RS=propofol+AND+sulfoalkyl. Accessed June 12, 2007.
24. CyDex, Inc. Captisol brochure. Available at: http://www.cydexinc.com/ whatiscaptisol.asp. Accessed September 25, 2006.
25. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Agnew Chem Int Ed Engl. 2002;41:266-270.
26. Welliver M. New drug sugammadex; a selective relaxant binding agent. AANA J. 2006;74:357-363.
27. Suy K, Morias K, Hans P, Heeringa M, Denmeyer I. Fast, effective and safe reversal of rocuronium and vecuronium-induced moderate neuromuscular block by the selective relaxant binding agent Org 25969 [abstract]. Anesthesiology. 2005;103:A1119.
28. Sacan O, Klein K, White PF. Sugammadex an alternative to neostigmine-glycopyrrolate and edrophonium-atropine for reversal of neuromuscular blockade [abstract]. Eur J Anaesthesiol. 2006;23(suppl 37):143-144.
29. Hartman J, Smeets JW, de Zwart, Peters SMA. In-vitro dialysabilty of sugammadex (Org 25969), a selective relaxant binding agent for reversal of neuromuscular block induced by rocuronium [abstract]. Eur J Anaesthesiol. 2006;23(suppl 37):144.
30. de Boer HD, van Egmond J, Marcus M, Schouten P, Smeets J, Driessen JJ. Pharmacokinetics of the selective relaxant binding agent sugammadex administered shortly after profound rocuronium-induced neuromuscular block. Poster presented at: European Society of Anesthesiologists Annual Meeting; June 2006; Madrid, Spain.
31. von Mach M, Burhenne J, Wellemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol. 2006;6:6. Available at: http://www.biomedcentral.com/1472-6904/6/ 6.
32. Itraconazole (Sporanox) [package insert]. Titusville, NJ: Janssen Pharmaceutica Products, LP; May 8, 2001.
33. Voricanazole (VFend) [package insert]. New York, NY: Pfizer, Inc; November 2006.
34. Thompson DO. Cyclodextrins - enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst. 1997;14:1-104.
35. Zannou EA, Streng WH, Stella VJ. Osmotic properties of sulfobutylether and hydroxypropyl cyclodextrins. Pharm Res. 2001;18:1226-1231.
36. Irie T, Otagiri M, Sunada M, et al. Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro. J Pharmacobiodyn. 1982;5:741-744.